^
    Back
    Association details:
    Biomarker:ATP5IF1 overexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy

    Published date:
    06/25/2020
    Excerpt:
    To determine the clinical significance of IF1 in HCC after sorafenib therapy, in situ hybridization assay was performed in tumor tissues from 59 HCC patients....Low disease free survival (DFS) (6.1 vs. 8.2 months, P = 0.0253) was found in the IF1 high-expressed group than the ones in low-expressed....
    DOI:
    10.3389/fonc.2020.01080
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Front Oncol
    Title:

    ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy

    Published date:
    06/25/2020
    Excerpt:
    IF1 overexpression attenuated the effect of sorafenib, and IF1 knockdown enhanced the effect...
    DOI:
    10.3389/fonc.2020.01080